Compare ELMD & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELMD | TTRX |
|---|---|---|
| Founded | 1992 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 326.9M | 285.1M |
| IPO Year | 2010 | 2025 |
| Metric | ELMD | TTRX |
|---|---|---|
| Price | $39.45 | $9.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $36.00 | $8.00 |
| AVG Volume (30 Days) | 48.1K | ★ 51.8K |
| Earning Date | 05-12-2026 | 05-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 46.55 | N/A |
| EPS | ★ 0.91 | N/A |
| Revenue | ★ $54,716,000.00 | N/A |
| Revenue This Year | $15.59 | N/A |
| Revenue Next Year | $11.51 | N/A |
| P/E Ratio | $43.96 | ★ N/A |
| Revenue Growth | ★ 13.83 | N/A |
| 52 Week Low | $19.93 | $2.57 |
| 52 Week High | $47.40 | $11.69 |
| Indicator | ELMD | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 44.85 | 51.22 |
| Support Level | $35.61 | $2.95 |
| Resistance Level | $43.61 | $10.72 |
| Average True Range (ATR) | 1.41 | 0.82 |
| MACD | -0.22 | -0.10 |
| Stochastic Oscillator | 19.53 | 32.45 |
Electromed Inc is a United States-based company that develops, manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest Airway Clearance System and related products, to patients with compromised pulmonary function with a commitment to excellence and compassionate service. The SmartVest System features a programmable air pulse generator, a therapy garment worn over the upper body and a connecting hose, which together provide safe, comfortable, and effective airway clearance therapy.
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.